Tradegate
16.12.25 | 17:05
3,840 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,760 | 3,900 | 16.12. | |
| 3,740 | 3,920 | 16.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Relmada Therapeutics passt Verträge für Führungskräfte an und erhöht Gehälter | 2 | Investing.com Deutsch | ||
| Mo | RELMADA THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.12. | Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology | 4 | GlobeNewswire (USA) | ||
| 19.11. | Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential | 1 | Investing.com | ||
| 14.11. | Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing | 6 | Seeking Alpha | ||
| 13.11. | Relmada Therapeutics GAAP EPS of -$0.30 | 5 | Seeking Alpha | ||
| 13.11. | Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates | 102 | GlobeNewswire (Europe) | Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key... ► Artikel lesen | |
| 13.11. | RELMADA THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| RELMADA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | A Glimpse of Relmada Therapeutics' Earnings Potential | 2 | Benzinga.com | ||
| 07.11. | Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 | 2 | GlobeNewswire (USA) | ||
| 06.11. | Hedge Fund and Insider Trading News: Ray Dalio, Ken Griffin, Bill Ackman, Point72 Asset Management, Balyasny Asset Management, Yacktman Asset Management, Relmada Therapeutics Inc (RLMD), Zoom Communications Inc (ZM), and More | 6 | Insider Monkey | ||
| 04.11. | Relmada Therapeutics-Aktie fällt nach 100-Millionen-Dollar-Kapitalerhöhung | 1 | Investing.com Deutsch | ||
| 04.11. | Relmada Therapeutics prices $100M securities offering | 1 | Seeking Alpha | ||
| 04.11. | Relmada Therapeutics prices $100 million stock offering at $2.20 per share | 1 | Investing.com | ||
| 04.11. | Relmada's NDV-01 shows 92% response rate in bladder cancer | 3 | Investing.com | ||
| 04.11. | Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 04.11. | Relmada Therapeutics: Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer | 152 | GlobeNewswire (Europe) | Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials - 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC... ► Artikel lesen | |
| 04.11. | RELMADA THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.10. | Relmada appoints Johns Hopkins professor to clinical advisory board | 2 | Investing.com | ||
| 07.10. | Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | +0,13 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| EVOTEC | 5,210 | +0,39 % | Nvidia darf wieder nach China exportieren, Evotec verliert Rückhalt, Bayer im Freudentaumel und BYD sorgt für Ärger bei der Bahn | Der Handel an den Börsenplätzen verläuft im Dezember bislang etwas ruhiger als im November und im Allgemeinen auch wieder mit positiver Tendenz. Zur Ruhe kommen die Marktakteure allerdings kaum, da... ► Artikel lesen | |
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,056 | -0,93 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| MODERNA | 25,415 | -0,10 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,588 | +0,39 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| AMGEN | 276,60 | -0,52 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,470 | -1,81 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 144,70 | -0,86 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| HEIDELBERG PHARMA | 2,510 | -2,71 % | HEIDELBERG PHARMA AG: Jetzt könnte die Ruhe trügen! | ||
| ILLUMINA | 111,64 | -0,29 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,200 | +1,26 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,920 | -3,03 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,283 | +2,15 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit |
Das Unternehmen RELMADA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELMADA THERAPEUTICS INC finden Sie auf Wallstreet Online.